A must attend event for any organisation seeking to bring their medicines, devices and diagnostics to UK patients.About this Event
GET the latest insights into strategy, HTA, pricing and policy
REVIEW and explore innovative data models and digital tools
IDENTIFY opportunities for accelerated access and growth
Our conference has been designed around three core market access areas. Each with a specific mission to bring you the latest insights and information for accelerating patient access.
1) Developments in strategy and HTA
The importance of patient engagement throughout the HTA process
Using patient registries in HTAs
Appraisal process of medical devices compared with drugs
Health economic modelling of digital apps
Access to Orphan Medicines: Developing policies for the future
2) Innovation tools
Approaches to utilising Real World Evidence (RWE)
Using analytics and big data to gain competitive advantage in Market Access
Collaborative working and horizon scanning
Harnessing digitals systems and technology to find new levels of patient value
3 ) Pricing and policy
VPAS – what you need to know
Updates on The Commercial Framework
Advanced Therapy Medicinal Products - Responding to new high cost / high value drugs
The NHS long term plan and what this actually means for pharma companies
Who should attend?
This conference should be attended by representatives from UK, European and global pharmaceutical, biotech, life science and medtech industries, as well as patient organisations and patient groups.
The job functions that will benefit most include:
- Heads of Market Access
- Country Managers
- Health Economists
- Commercial Directors
- Marketing Directors
- Managing Directors
- Chief Executives
- Medical Directors
- Policy Officers/Executives
- Policy Advisors
Event Venue
Royal College of Physicians, 11 Saint Andrews Place, London, United Kingdom
GBP 0.00 to GBP 500.00